67
Participants
Start Date
August 31, 2017
Primary Completion Date
September 30, 2019
Study Completion Date
September 30, 2019
Netupitant
Netupitant 1.33 mg/kg oral suspension up to a maximum of 100 mg
Palonosetron
Palonosetron 20 μg/kg solution for oral use up to a maximum of 1.5 mg
Netupitant
Netupitant 4 mg/kg oral suspension up to a maximum of 300 mg
Palonosetron
Palonosetron 20 μg/kg solution for oral use up to a maximum of 1.5 mg
Nemours/A.I. duPont Hospital for Children, Wilmington
Medical University of South Carolina, Charleston
Nemours Children's Clinic, Jacksonville
Nemours Children's Hospital - Orlando, Orlando
Dnipropetrovsk Regional Children's Clinical Hospital, Dnipro
Voronezh Regional Children's Cinical Hospital #1, Voronezh
Maine Medical Center - Cancer Medicine and Blood Disorders - Scarborough, Scarborough
Chelyabinsk Regional Children's Clinical Hospital, Chelyabinsk
Children's Territorial Clinical Hospital, Krasnodar
Dmitry Rogachev National Scientific and Practical Center for Pediatric Hematology, Oncology and Immunology, Moscow
City Clinical Hospital #31, Saint Petersburg
First I.P. Pavlov State Medical University of St. Petersburg, Saint Petersburg
Regional Children's Clinical Hospital #1, Yekaterinburg
University Children's Hospital, Center for Pediatrics, Department of Hematology and Oncology, Belgrade
Clinical Center Nis, Clinic of Pediatric Internal Diseases, Niš
National Institute of Cancer, Research Department of Pediatric Oncology, Kyiv
West Ukrainian Specialized Children's Medical Center, Department of Pediatric Surgery, Lviv
Lead Sponsor
Helsinn Healthcare SA
INDUSTRY